newsfilter
← Latest News
GlobeNewswire·

Alps Group Inc Reports Fiscal Year 2026 Financial Results and Provides Business Update

ALPS
  • Alps Group Inc. reported a 44% revenue increase to $4.9 million for the fiscal year ended March 31, 2026.
  • The company began trading on the Nasdaq Global Market under the ticker "ALPS" in October 2025 following a business combination with Globalink Investment Inc.
  • Net loss for the fiscal year 2026 was $2.1 million, a reduction from $2.6 million in the prior year.
  • Gross profit rose to $1.6 million, though the gross margin decreased to approximately 32% due to revenue mix shifts in aesthetic services.
  • Research and development expenses dropped to $61,155 as the company discontinued its COVID-19 mRNA vaccine candidate to focus on NK Cell Therapy and mRNA diagnostics.
  • Administrative expenses increased to $3.5 million, with $1.16 million attributed to professional fees related to the business combination.
  • MyGenome Sdn. Bhd. expanded its accreditation to include Whole Genome Sequencing under MS ISO 15189:2022 standards.
  • The company appointed Cheing Lye-Ping as Chief Financial Officer and Lee Hee Hang to the Board of Directors.
  • MyImmune, the Natural Killer Cell Therapy program, completed its optimization phase and is progressing toward process validation.
  • An agreement was signed to establish a clinically validated Patient-Derived Organoid platform in Malaysia.
  • The company filed its Form 20-F annual report with the SEC on August 6, 2026.
  • Cash and cash equivalents at the end of the fiscal year 2026 totaled $607,473.